Exemestane following tamoxifen in postmenopausal women with primary breast cancer.
Mouridsen
Henning T
HT
D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D015519:Bone Density; D001862:Bone Resorption / Q000139:chemically induced*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D012307:Risk Factors; D013629:Tamoxifen / Q000008:administration & dosage* / Q000627:therapeutic use*
D000730:Androstadienes; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D013629:Tamoxifen; C056516:exemestane